Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Tuberculosis Infection, Latent Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

2 recruiting trials for Tuberculosis Infection, Latent. Eligibility criteria explained in plain English.

TrialFinderData lists 2 Tuberculosis Infection, Latent clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 2 / Phase 3 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by McGill University Health Centre/Research Institute of the McGill University Health Centre (1), Pontificia Universidad Catolica de Chile (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is rifampin standard arm (drug, 1 trial), followed by rifampin double dose, levofloxacin and rifapentine.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
2
Total Trials
2
Recruiting Now
0
Phase 3 Trials
2
Sponsors

Track Tuberculosis Infection, Latent trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2 / Phase 3NCT06498414

Shorter and Safer Treatment Regimens for Latent TB

Our study rationale is based on: 1. Tuberculosis Preventive Treatment (TPT) is given to healthy people and needs to be safe; 2. Tuberculosis Preventive Treatment (TPT) with...

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health CentreEnrolling: 180014 locations
RECRUITINGNCT07086820

Window Prophylaxis for Pediatric Tuberculosis Prevention Trial

The goal of this cluster-randomized controlled trial is to evaluate the effectiveness of tuberculosis preventive treatment (TPT) administered during the "window period" to prevent...

Sponsor: Pontificia Universidad Catolica de ChileEnrolling: 64713 locations

Frequently Asked Questions

There are currently 2 clinical trials for Tuberculosis Infection, Latent, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Tuberculosis Infection, Latent, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Tuberculosis Infection, Latent, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.